Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OncoSil Medical Ltd ( (AU:OSL) ) has issued an update.
OncoSil Medical Limited announced promising interim results from the OSPREY registry, showing improved survival rates for LAPC patients treated with the OncoSil™ device and chemotherapy. The findings indicate a significant survival advantage compared to standard chemotherapy alone, with a favorable safety profile, potentially impacting the company’s market position and offering hope for improved patient outcomes.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC).
Average Trading Volume: 25,324
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$21.04M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.